Trials / Terminated
TerminatedNCT05559125
A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects
An Open-label, Single-ascending Dose Phase I Study to Evaluate the Safety and Tolerability of STSA-1002 Combined With STSA-1005 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | STSA-1002 Injection | Intravenous injection |
| DRUG | STSA-1005 Injection | Intravenous injection |
Timeline
- Start date
- 2022-11-08
- Primary completion
- 2024-03-26
- Completion
- 2024-03-26
- First posted
- 2022-09-29
- Last updated
- 2024-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05559125. Inclusion in this directory is not an endorsement.